Aptinyx falls on planned equity raise

Aptinyx

21/10/2020 13:58

** Aptinyx Inc  APTX.O  shares down ~7% premarket as co
looks to raise equity
    ** After the bell Tues, biopharma launched 12 mln share
offering to advance development of its brain and nervous system
disorders treatments  urn:newsml:reuters.com:*:nBw7gYNsMa
    ** SVB Leerink, Piper Sandler and Cantor jt bookrunners for
offering slated to price Weds AMC
    ** APTX surged 17.4% to close at $4.30 on Tues after co late
Mon said treatment for post-traumatic stress disorder (PTSD),
NYX-783, showed statistically significant and clinically
meaningful efficacy results in mid-stage study  urn:newsml:reuters.com:*:nBwc2lh2Pa
    ** US FDA granted co a fast track designation for
development of NYX-783
    ** APTX has ~47 mln shares outstanding for ~$200 mln market
cap, per Refinitiv data
    ** Stock up ~26% in 2020

 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper.tr.com@reuters.net
lance.tupper@tr.com))